aspirin has been researched along with umirolimus in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aarøe, J; Bøtker, HE; Christiansen, EH; Hansen, KN; Jensen, LO; Kaltoft, A; Kristensen, SD; Krusell, LR; Lassen, JF; Madsen, M; Maeng, M; Ravkilde, J; Terkelsen, CJ; Thayssen, P; Thuesen, L; Tilsted, HH; Villadsen, AB | 1 |
| den Heijer, P; Goy, JJ; Hofma, S; Nouche, RT; Serra, A; Slagboom, T; Smits, PC; Togni, M; Valdés, M; van der Ent, M; Vázquez, N; Voudris, V; Vuillomenet, A | 1 |
| Alber, H; Buser, P; Conen, D; Eberli, F; Galatius, S; Gilgen, N; Hoffmann, A; Jeger, R; Kaiser, C; Kurz, DJ; Moccetti, T; Müller, C; Naber, C; Pedrazzini, G; Pfisterer, M; Rickenbacher, P; Rickli, H; Skov Jensen, J; Steiner, M; Vogt, DR; Von Felten, S; Vuillomenet, A; Wadt Hansen, K; Wanitschek, M; Weilenmann, D | 1 |
| Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW | 1 |
| Akasaka, T; Hanawa, K; Hao, K; Hasebe, Y; Hirano, M; Ito, K; Matsumoto, Y; Miyata, S; Nishimiya, K; Ogata, T; Oyama, K; Shimokawa, H; Shindo, T; Takahashi, J; Tanaka, A; Taruya, A; Tsuburaya, R; Uzuka, H | 1 |
| Garcia-Garcia, HM; Hamm, C; Jüni, P; Serruys, PW; Steg, PG; Valgimigli, M; van Es, GA; Vranckx, P; Windecker, S | 1 |
| Abdul, F; Anderson, R; Butt, M; Chase, A; Choudhury, A; Gallagher, S; Hailan, A; Kinnaird, T; Ossei-Gerning, N; Smith, D; Yazji, K | 1 |
| Cho, DK; Choi, JH; Choi, SH; Doh, JH; Gwon, HC; Hahn, JY; Kim, SH; Lee, JB; Lee, JM; Lee, SH; Oh, JH; Park, TK; Song, YB; Yang, JH | 1 |
| Hayashi, K; Kawashiri, MA; Mori, M; Nakahashi, T; Nakanishi, C; Okada, H; Sakata, K; Shimojima, M; Takuwa, Y; Yamagishi, M; Yokawa, JI; Yoshida, S; Yoshimuta, T; Yoshioka, K | 1 |
| Cho, DK; Choi, S; Hong, BK; Hong, MK; Jang, Y; Jeon, DW; Kang, TS; Kang, WC; Kim, BK; Kim, BO; Kim, JS; Kim, S; Kim, YH; Kwon, HM; Lee, BK; Lee, OH; Min, PK; Shin, DH; Woo, SI; Yoon, YW | 1 |
| Ako, J; Ando, K; Anzai, H; Fujii, K; Hamasaki, T; Iijima, R; Inoue, K; Inoue, T; Ishiwata, S; Ito, Y; Kadotani, M; Kataoka, T; Kawaguchi, K; Kawata, M; Kinutani, H; Kuroda, K; Morita, T; Nakamura, M; Niinuma, H; Nishida, Y; Ochiai, M; Ohira, H; Okada, H; Omiya, K; Otake, H; Shinke, T; Takiuchi, S; Tanaka, H; Ueda, Y; Urasawa, K; Yasaka, Y; Yokoi, H; Yoshiyama, M; Zen, K | 1 |
| Anderson, R; Chang, CC; Chichareon, P; Chowdhary, S; Fath-Ordoubadi, F; Galasko, G; Garg, S; Hamm, CW; Hoole, S; Jüni, P; Kogame, N; Kukreja, N; Modolo, R; Oldroyd, KG; Onuma, Y; Serruys, PW; Stables, RH; Steg, PG; Takahashi, K; Tomaniak, M; Valgimigli, M; Windecker, S; Zaman, A | 1 |
8 trial(s) available for aspirin and umirolimus
| Article | Year |
|---|---|
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Retreatment; Sirolimus | 2013 |
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Topics: Absorbable Implants; Aspirin; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Materials Testing; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Prospective Studies; Sirolimus | 2013 |
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome tria
Topics: Absorbable Implants; Aged; Anti-Inflammatory Agents; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Metals; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Polymers; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Sirolimus; Stents; Switzerland; Thiophenes; Treatment Outcome | 2015 |
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Combinations; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Sirolimus; Ticagrelor; Time; Treatment Outcome; Young Adult | 2016 |
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Monitoring; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Republic of Korea; Sirolimus; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2018 |
Vascular response to biolimus A-9 eluting stent in patients with shorter and prolonged dual antiplatelet therapy: optical coherence tomography sub-study of the NIPPON trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyridines; Retrospective Studies; Single-Blind Method; Sirolimus; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Resistance | 2018 |
Impact of established cardiovascular disease on outcomes in the randomized global leaders trial.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Heart Disease Risk Factors; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Assessment; Sirolimus; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
4 other study(ies) available for aspirin and umirolimus
| Article | Year |
|---|---|
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
Topics: Absorbable Implants; Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Prosthesis Design; Sirolimus; Ticlopidine; Treatment Outcome | 2015 |
Accuracy of optical frequency domain imaging for evaluation of coronary adventitial vasa vasorum formation after stent implantation in pigs and humans - a validation study - .
Topics: Adventitia; Aged; Aged, 80 and over; Animals; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vessels; Disease Progression; Drug-Eluting Stents; Everolimus; Female; Humans; Interferometry; Male; Middle Aged; Neointima; Neovascularization, Physiologic; Platelet Aggregation Inhibitors; Postoperative Period; Prosthesis Implantation; Sirolimus; Stents; Swine; Swine, Miniature; Ticlopidine; Tomography, Optical Coherence; Vasa Vasorum; Vasculitis | 2015 |
Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Prospective Studies; Risk Factors; Sirolimus; Treatment Outcome | 2016 |
Early endothelialization associated with a biolimus A9 bioresorbable polymer stent in a porcine coronary model.
Topics: Absorbable Implants; Animals; Aspirin; Coronary Stenosis; Coronary Vessels; Drug-Eluting Stents; Endothelium, Vascular; Humans; Metals; Platelet Aggregation Inhibitors; Prosthesis Design; Sirolimus; Swine | 2017 |